机译:基于模型的药物开发:定量药理学之路
Bristol Myers-Squibb Princeton New Jersey;
Drug Disposition and Global PK/PD Lilly Research Laboratories Eli Lilly ampamp Co. Lilly Corporate Center Indianapolis IN 46285 USA;
Drug Disposition and Global PK/PD Lilly Research Laboratories Eli Lilly ampamp Co. Lilly Corporate Center Indianapolis IN 46285 USA;
Drug Disposition and Global PK/PD Lilly Research Laboratories Eli Lilly ampamp Co. Lilly Corporate Center Indianapolis IN 46285 USA;
Drug Disposition and Global PK/PD Lilly Research Laboratories Eli Lilly ampamp Co. Lilly Corporate Center Indianapolis IN 46285 USA;
Drug Disposition and Global PK/PD Lilly Research Laboratories Eli Lilly ampamp Co. Lilly Corporate Center Indianapolis IN 46285 USA;
Drug Disposition and Global PK/PD Lilly Research Laboratories Eli Lilly ampamp Co. Lilly Corporate Center Indianapolis IN 46285 USA;
model-based drug development; quantitative pharmacology; disease model; drug exposure-response model; knowledge management; decision making; gemcitabine; raloxifene;
机译:基于模型的药物开发:定量药理学之路。
机译:下一代基于模型的药物发现和开发:定量和系统药理学。
机译:定量药理学和基于模型的药物开发中的概念和挑战
机译:高通量微电极阵列平台,用于使用自发活性神经组织进行定量药理,毒理学和药物开发
机译:LC-MS / MS定量方法开发,用于抗癌药的药理研究。
机译:定量药理学和基于模型的药物开发中的概念和挑战
机译:定量药理学和基于模型的药物开发中的概念和挑战